Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

A Study in Head and Neck Cancer
A Randomized, Double-Blind, Phase 2 Safety Study of Cetuximab, Using ImClone Versus Boehringer Ingelheim Manufacturing Processes, in Combination With Cisplatin or Carboplatin and 5-Fluorouracil in the First-Line Treatment of Patients With Locoregionally Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated:  2/18/2016
Clinical Research Facility
mi
from
Grand Junction, CO
A Study in Head and Neck Cancer
A Randomized, Double-Blind, Phase 2 Safety Study of Cetuximab, Using ImClone Versus Boehringer Ingelheim Manufacturing Processes, in Combination With Cisplatin or Carboplatin and 5-Fluorouracil in the First-Line Treatment of Patients With Locoregionally Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated: 2/18/2016
Clinical Research Facility
mi
from
Grand Junction, CO
Click here to add this to my saved trials
A Study in Head and Neck Cancer
A Randomized, Double-Blind, Phase 2 Safety Study of Cetuximab, Using ImClone Versus Boehringer Ingelheim Manufacturing Processes, in Combination With Cisplatin or Carboplatin and 5-Fluorouracil in the First-Line Treatment of Patients With Locoregionally Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated:  2/18/2016
Clinical Research Facility
mi
from
Weston, FL
A Study in Head and Neck Cancer
A Randomized, Double-Blind, Phase 2 Safety Study of Cetuximab, Using ImClone Versus Boehringer Ingelheim Manufacturing Processes, in Combination With Cisplatin or Carboplatin and 5-Fluorouracil in the First-Line Treatment of Patients With Locoregionally Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated: 2/18/2016
Clinical Research Facility
mi
from
Weston, FL
Click here to add this to my saved trials
A Study in Head and Neck Cancer
A Randomized, Double-Blind, Phase 2 Safety Study of Cetuximab, Using ImClone Versus Boehringer Ingelheim Manufacturing Processes, in Combination With Cisplatin or Carboplatin and 5-Fluorouracil in the First-Line Treatment of Patients With Locoregionally Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated:  2/18/2016
Clinical Research Facility
mi
from
Albany, GA
A Study in Head and Neck Cancer
A Randomized, Double-Blind, Phase 2 Safety Study of Cetuximab, Using ImClone Versus Boehringer Ingelheim Manufacturing Processes, in Combination With Cisplatin or Carboplatin and 5-Fluorouracil in the First-Line Treatment of Patients With Locoregionally Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated: 2/18/2016
Clinical Research Facility
mi
from
Albany, GA
Click here to add this to my saved trials
A Study in Head and Neck Cancer
A Randomized, Double-Blind, Phase 2 Safety Study of Cetuximab, Using ImClone Versus Boehringer Ingelheim Manufacturing Processes, in Combination With Cisplatin or Carboplatin and 5-Fluorouracil in the First-Line Treatment of Patients With Locoregionally Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated:  2/18/2016
Clinical Research Facility
mi
from
Chicago, IL
A Study in Head and Neck Cancer
A Randomized, Double-Blind, Phase 2 Safety Study of Cetuximab, Using ImClone Versus Boehringer Ingelheim Manufacturing Processes, in Combination With Cisplatin or Carboplatin and 5-Fluorouracil in the First-Line Treatment of Patients With Locoregionally Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated: 2/18/2016
Clinical Research Facility
mi
from
Chicago, IL
Click here to add this to my saved trials
A Study in Head and Neck Cancer
A Randomized, Double-Blind, Phase 2 Safety Study of Cetuximab, Using ImClone Versus Boehringer Ingelheim Manufacturing Processes, in Combination With Cisplatin or Carboplatin and 5-Fluorouracil in the First-Line Treatment of Patients With Locoregionally Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated:  2/18/2016
Clinical Research Facility
mi
from
Springfield, IL
A Study in Head and Neck Cancer
A Randomized, Double-Blind, Phase 2 Safety Study of Cetuximab, Using ImClone Versus Boehringer Ingelheim Manufacturing Processes, in Combination With Cisplatin or Carboplatin and 5-Fluorouracil in the First-Line Treatment of Patients With Locoregionally Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated: 2/18/2016
Clinical Research Facility
mi
from
Springfield, IL
Click here to add this to my saved trials
A Study in Head and Neck Cancer
A Randomized, Double-Blind, Phase 2 Safety Study of Cetuximab, Using ImClone Versus Boehringer Ingelheim Manufacturing Processes, in Combination With Cisplatin or Carboplatin and 5-Fluorouracil in the First-Line Treatment of Patients With Locoregionally Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated:  2/18/2016
Clinical Research Facility
mi
from
New Albany, IN
A Study in Head and Neck Cancer
A Randomized, Double-Blind, Phase 2 Safety Study of Cetuximab, Using ImClone Versus Boehringer Ingelheim Manufacturing Processes, in Combination With Cisplatin or Carboplatin and 5-Fluorouracil in the First-Line Treatment of Patients With Locoregionally Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated: 2/18/2016
Clinical Research Facility
mi
from
New Albany, IN
Click here to add this to my saved trials
A Study in Head and Neck Cancer
A Randomized, Double-Blind, Phase 2 Safety Study of Cetuximab, Using ImClone Versus Boehringer Ingelheim Manufacturing Processes, in Combination With Cisplatin or Carboplatin and 5-Fluorouracil in the First-Line Treatment of Patients With Locoregionally Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated:  2/18/2016
Clinical Research Facility
mi
from
Wichita, KA
A Study in Head and Neck Cancer
A Randomized, Double-Blind, Phase 2 Safety Study of Cetuximab, Using ImClone Versus Boehringer Ingelheim Manufacturing Processes, in Combination With Cisplatin or Carboplatin and 5-Fluorouracil in the First-Line Treatment of Patients With Locoregionally Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated: 2/18/2016
Clinical Research Facility
mi
from
Wichita, KA
Click here to add this to my saved trials
A Study in Head and Neck Cancer
A Randomized, Double-Blind, Phase 2 Safety Study of Cetuximab, Using ImClone Versus Boehringer Ingelheim Manufacturing Processes, in Combination With Cisplatin or Carboplatin and 5-Fluorouracil in the First-Line Treatment of Patients With Locoregionally Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated:  2/18/2016
Clinical Research Facility
mi
from
Albany, NY
A Study in Head and Neck Cancer
A Randomized, Double-Blind, Phase 2 Safety Study of Cetuximab, Using ImClone Versus Boehringer Ingelheim Manufacturing Processes, in Combination With Cisplatin or Carboplatin and 5-Fluorouracil in the First-Line Treatment of Patients With Locoregionally Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated: 2/18/2016
Clinical Research Facility
mi
from
Albany, NY
Click here to add this to my saved trials
A Study in Head and Neck Cancer
A Randomized, Double-Blind, Phase 2 Safety Study of Cetuximab, Using ImClone Versus Boehringer Ingelheim Manufacturing Processes, in Combination With Cisplatin or Carboplatin and 5-Fluorouracil in the First-Line Treatment of Patients With Locoregionally Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated:  2/18/2016
Clinical Research Facility
mi
from
New York, NY
A Study in Head and Neck Cancer
A Randomized, Double-Blind, Phase 2 Safety Study of Cetuximab, Using ImClone Versus Boehringer Ingelheim Manufacturing Processes, in Combination With Cisplatin or Carboplatin and 5-Fluorouracil in the First-Line Treatment of Patients With Locoregionally Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated: 2/18/2016
Clinical Research Facility
mi
from
New York, NY
Click here to add this to my saved trials
A Study in Head and Neck Cancer
A Randomized, Double-Blind, Phase 2 Safety Study of Cetuximab, Using ImClone Versus Boehringer Ingelheim Manufacturing Processes, in Combination With Cisplatin or Carboplatin and 5-Fluorouracil in the First-Line Treatment of Patients With Locoregionally Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated:  2/18/2016
Clinical Research Facility
mi
from
Portland, OR
A Study in Head and Neck Cancer
A Randomized, Double-Blind, Phase 2 Safety Study of Cetuximab, Using ImClone Versus Boehringer Ingelheim Manufacturing Processes, in Combination With Cisplatin or Carboplatin and 5-Fluorouracil in the First-Line Treatment of Patients With Locoregionally Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated: 2/18/2016
Clinical Research Facility
mi
from
Portland, OR
Click here to add this to my saved trials
A Study in Head and Neck Cancer
A Randomized, Double-Blind, Phase 2 Safety Study of Cetuximab, Using ImClone Versus Boehringer Ingelheim Manufacturing Processes, in Combination With Cisplatin or Carboplatin and 5-Fluorouracil in the First-Line Treatment of Patients With Locoregionally Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated:  2/18/2016
Clinical Research Facility
mi
from
Charleston, SC
A Study in Head and Neck Cancer
A Randomized, Double-Blind, Phase 2 Safety Study of Cetuximab, Using ImClone Versus Boehringer Ingelheim Manufacturing Processes, in Combination With Cisplatin or Carboplatin and 5-Fluorouracil in the First-Line Treatment of Patients With Locoregionally Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated: 2/18/2016
Clinical Research Facility
mi
from
Charleston, SC
Click here to add this to my saved trials
A Study in Head and Neck Cancer
A Randomized, Double-Blind, Phase 2 Safety Study of Cetuximab, Using ImClone Versus Boehringer Ingelheim Manufacturing Processes, in Combination With Cisplatin or Carboplatin and 5-Fluorouracil in the First-Line Treatment of Patients With Locoregionally Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated:  2/18/2016
Clinical Research Facility
mi
from
Abilene, TX
A Study in Head and Neck Cancer
A Randomized, Double-Blind, Phase 2 Safety Study of Cetuximab, Using ImClone Versus Boehringer Ingelheim Manufacturing Processes, in Combination With Cisplatin or Carboplatin and 5-Fluorouracil in the First-Line Treatment of Patients With Locoregionally Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated: 2/18/2016
Clinical Research Facility
mi
from
Abilene, TX
Click here to add this to my saved trials
A Study in Head and Neck Cancer
A Randomized, Double-Blind, Phase 2 Safety Study of Cetuximab, Using ImClone Versus Boehringer Ingelheim Manufacturing Processes, in Combination With Cisplatin or Carboplatin and 5-Fluorouracil in the First-Line Treatment of Patients With Locoregionally Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated:  2/18/2016
mi
from
Calgary,
A Study in Head and Neck Cancer
A Randomized, Double-Blind, Phase 2 Safety Study of Cetuximab, Using ImClone Versus Boehringer Ingelheim Manufacturing Processes, in Combination With Cisplatin or Carboplatin and 5-Fluorouracil in the First-Line Treatment of Patients With Locoregionally Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated: 2/18/2016
mi
from
Calgary,
Click here to add this to my saved trials
Targeted T Cells After Neoadjuvant Chemotherapy in Treating Women With Stage II or III Breast Cancer Undergoing Surgery
A Phase II Study of Anti-CD3 x Anti-HER2/Neu (Her2Bi) Armed Activated T Cells (ATC) After Neoadjuvant Chemotherapy in Women With HER2/Neu (0-2+), Hormone Receptor (HR) Negative Stage II-III Breast Cancers
Status: Enrolling
Updated:  2/18/2016
Barbara Ann Karmanos Cancer Institute
mi
from
Detroit, MI
Targeted T Cells After Neoadjuvant Chemotherapy in Treating Women With Stage II or III Breast Cancer Undergoing Surgery
A Phase II Study of Anti-CD3 x Anti-HER2/Neu (Her2Bi) Armed Activated T Cells (ATC) After Neoadjuvant Chemotherapy in Women With HER2/Neu (0-2+), Hormone Receptor (HR) Negative Stage II-III Breast Cancers
Status: Enrolling
Updated: 2/18/2016
Barbara Ann Karmanos Cancer Institute
mi
from
Detroit, MI
Click here to add this to my saved trials
TRC105 for Liver Cancer That Has Not Responded to Sorafenib
A Phase II Study of TRC105 in Patients With Hepatocellular Carcinoma (HCC) Who Have Progressed on Sorafenib
Status: Enrolling
Updated:  2/18/2016
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
TRC105 for Liver Cancer That Has Not Responded to Sorafenib
A Phase II Study of TRC105 in Patients With Hepatocellular Carcinoma (HCC) Who Have Progressed on Sorafenib
Status: Enrolling
Updated: 2/18/2016
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors
A Phase Ib, Multi-center, Open Label, Dose Escalation Study of Oral LDE225 in Combination With BKM 120 in Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  2/18/2016
Cedars Sinai Medical Center SC
mi
from
Los Angeles, CA
Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors
A Phase Ib, Multi-center, Open Label, Dose Escalation Study of Oral LDE225 in Combination With BKM 120 in Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 2/18/2016
Cedars Sinai Medical Center SC
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors
A Phase Ib, Multi-center, Open Label, Dose Escalation Study of Oral LDE225 in Combination With BKM 120 in Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  2/18/2016
University of California San Francisco UCSF (SC)
mi
from
San Francisco, CA
Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors
A Phase Ib, Multi-center, Open Label, Dose Escalation Study of Oral LDE225 in Combination With BKM 120 in Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 2/18/2016
University of California San Francisco UCSF (SC)
mi
from
San Francisco, CA
Click here to add this to my saved trials
Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors
A Phase Ib, Multi-center, Open Label, Dose Escalation Study of Oral LDE225 in Combination With BKM 120 in Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  2/18/2016
H. Lee Moffitt Cancer Center & Research Institute Moffitt 4
mi
from
Tampa, FL
Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors
A Phase Ib, Multi-center, Open Label, Dose Escalation Study of Oral LDE225 in Combination With BKM 120 in Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 2/18/2016
H. Lee Moffitt Cancer Center & Research Institute Moffitt 4
mi
from
Tampa, FL
Click here to add this to my saved trials
Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors
A Phase Ib, Multi-center, Open Label, Dose Escalation Study of Oral LDE225 in Combination With BKM 120 in Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  2/18/2016
Dana Farber Cancer Institute Dana SC
mi
from
Boston, MA
Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors
A Phase Ib, Multi-center, Open Label, Dose Escalation Study of Oral LDE225 in Combination With BKM 120 in Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 2/18/2016
Dana Farber Cancer Institute Dana SC
mi
from
Boston, MA
Click here to add this to my saved trials
Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors
A Phase Ib, Multi-center, Open Label, Dose Escalation Study of Oral LDE225 in Combination With BKM 120 in Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  2/18/2016
Mayo Clinic - Rochester Division of Hematology
mi
from
Rochester, MN
Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors
A Phase Ib, Multi-center, Open Label, Dose Escalation Study of Oral LDE225 in Combination With BKM 120 in Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 2/18/2016
Mayo Clinic - Rochester Division of Hematology
mi
from
Rochester, MN
Click here to add this to my saved trials
Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors
A Phase Ib, Multi-center, Open Label, Dose Escalation Study of Oral LDE225 in Combination With BKM 120 in Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  2/18/2016
Duke University Medical Center Duke - Baker
mi
from
Durham, NC
Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors
A Phase Ib, Multi-center, Open Label, Dose Escalation Study of Oral LDE225 in Combination With BKM 120 in Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 2/18/2016
Duke University Medical Center Duke - Baker
mi
from
Durham, NC
Click here to add this to my saved trials
Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors
A Phase Ib, Multi-center, Open Label, Dose Escalation Study of Oral LDE225 in Combination With BKM 120 in Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  2/18/2016
Willamette Valley Clinical Studies Williamette Valley Cancer
mi
from
Eugene, OR
Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors
A Phase Ib, Multi-center, Open Label, Dose Escalation Study of Oral LDE225 in Combination With BKM 120 in Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 2/18/2016
Willamette Valley Clinical Studies Williamette Valley Cancer
mi
from
Eugene, OR
Click here to add this to my saved trials
Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors
A Phase Ib, Multi-center, Open Label, Dose Escalation Study of Oral LDE225 in Combination With BKM 120 in Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  2/18/2016
Fox Chase Cancer Center FCCC
mi
from
Philadelphia, PA
Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors
A Phase Ib, Multi-center, Open Label, Dose Escalation Study of Oral LDE225 in Combination With BKM 120 in Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 2/18/2016
Fox Chase Cancer Center FCCC
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors
A Phase Ib, Multi-center, Open Label, Dose Escalation Study of Oral LDE225 in Combination With BKM 120 in Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  2/18/2016
Sammons Cancer Center - Texas Oncology SC-2
mi
from
Dallas, TX
Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors
A Phase Ib, Multi-center, Open Label, Dose Escalation Study of Oral LDE225 in Combination With BKM 120 in Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 2/18/2016
Sammons Cancer Center - Texas Oncology SC-2
mi
from
Dallas, TX
Click here to add this to my saved trials
Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors
A Phase Ib, Multi-center, Open Label, Dose Escalation Study of Oral LDE225 in Combination With BKM 120 in Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  2/18/2016
University of Texas/MD Anderson Cancer Center SC-3
mi
from
Houston, TX
Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors
A Phase Ib, Multi-center, Open Label, Dose Escalation Study of Oral LDE225 in Combination With BKM 120 in Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 2/18/2016
University of Texas/MD Anderson Cancer Center SC-3
mi
from
Houston, TX
Click here to add this to my saved trials
Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors
A Phase Ib, Multi-center, Open Label, Dose Escalation Study of Oral LDE225 in Combination With BKM 120 in Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  2/18/2016
University of Utah / Huntsman Cancer Institute Huntsman
mi
from
Salt Lake City, UT
Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors
A Phase Ib, Multi-center, Open Label, Dose Escalation Study of Oral LDE225 in Combination With BKM 120 in Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 2/18/2016
University of Utah / Huntsman Cancer Institute Huntsman
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors
A Phase Ib, Multi-center, Open Label, Dose Escalation Study of Oral LDE225 in Combination With BKM 120 in Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  2/18/2016
Northwest Cancer Specialists Northwest Cancer
mi
from
Portland, OR
Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors
A Phase Ib, Multi-center, Open Label, Dose Escalation Study of Oral LDE225 in Combination With BKM 120 in Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 2/18/2016
Northwest Cancer Specialists Northwest Cancer
mi
from
Portland, OR
Click here to add this to my saved trials
Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors
A Phase Ib, Multi-center, Open Label, Dose Escalation Study of Oral LDE225 in Combination With BKM 120 in Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  2/18/2016
Texas Oncology Midtown Texas Oncology
mi
from
Dallas, TX
Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors
A Phase Ib, Multi-center, Open Label, Dose Escalation Study of Oral LDE225 in Combination With BKM 120 in Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 2/18/2016
Texas Oncology Midtown Texas Oncology
mi
from
Dallas, TX
Click here to add this to my saved trials
Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors
A Phase Ib, Multi-center, Open Label, Dose Escalation Study of Oral LDE225 in Combination With BKM 120 in Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  2/18/2016
Novartis Investigative Site
mi
from
Parkville,
Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors
A Phase Ib, Multi-center, Open Label, Dose Escalation Study of Oral LDE225 in Combination With BKM 120 in Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 2/18/2016
Novartis Investigative Site
mi
from
Parkville,
Click here to add this to my saved trials
Ponatinib for Advanced Medullary Thyroid Cancer
A Phase II Study of Ponatinib in Advanced or Metastatic Medullary Thyroid Cancer
Status: Enrolling
Updated:  2/18/2016
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Ponatinib for Advanced Medullary Thyroid Cancer
A Phase II Study of Ponatinib in Advanced or Metastatic Medullary Thyroid Cancer
Status: Enrolling
Updated: 2/18/2016
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Impacts of Exercise on Prognostic Biomarkers in Lung Cancer Patients
Impacts of Exercise on Prognostic Biomarkers in Lung Cancer Patients
Status: Enrolling
Updated:  2/18/2016
University of Wisconsin-Madison
mi
from
Madison, WI
Impacts of Exercise on Prognostic Biomarkers in Lung Cancer Patients
Impacts of Exercise on Prognostic Biomarkers in Lung Cancer Patients
Status: Enrolling
Updated: 2/18/2016
University of Wisconsin-Madison
mi
from
Madison, WI
Click here to add this to my saved trials
Impacts of Exercise on Prognostic Biomarkers in Lung Cancer Patients
Impacts of Exercise on Prognostic Biomarkers in Lung Cancer Patients
Status: Enrolling
Updated:  2/18/2016
UW Health Oncology - 1 South Park
mi
from
Madison, WI
Impacts of Exercise on Prognostic Biomarkers in Lung Cancer Patients
Impacts of Exercise on Prognostic Biomarkers in Lung Cancer Patients
Status: Enrolling
Updated: 2/18/2016
UW Health Oncology - 1 South Park
mi
from
Madison, WI
Click here to add this to my saved trials
Evaluation of Cetuximab (ERBITUX) and Concurrent Carboplatin, Paclitaxel & Radiotherapy in the Management of Patients With Advanced Locoregional Squamous Cell Carcinomas of the Head and Neck (GCC 0442)
A Phase II Study of Evaluation of Cetuximab (ERBITUX) and Concurrent Carboplatin, Paclitaxel & Radiotherapy in the Management of Patients With Advanced Locoregional Squamous Cell Carcinomas of the Head and Neck
Status: Enrolling
Updated:  2/18/2016
University of Maryland & Baltimore VA medical centre
mi
from
Baltimore, MD
Evaluation of Cetuximab (ERBITUX) and Concurrent Carboplatin, Paclitaxel & Radiotherapy in the Management of Patients With Advanced Locoregional Squamous Cell Carcinomas of the Head and Neck (GCC 0442)
A Phase II Study of Evaluation of Cetuximab (ERBITUX) and Concurrent Carboplatin, Paclitaxel & Radiotherapy in the Management of Patients With Advanced Locoregional Squamous Cell Carcinomas of the Head and Neck
Status: Enrolling
Updated: 2/18/2016
University of Maryland & Baltimore VA medical centre
mi
from
Baltimore, MD
Click here to add this to my saved trials
A Phase II Protocol of Arsenic Trioxide (Trisenox) in Subjects With Advanced Primary Carcinoma of the Liver
A Phase II Protocol of Arsenic Trioxide (Trisenox) in Subjects With Advanced Primary Carcinoma of the Liver
Status: Enrolling
Updated:  2/18/2016
University of Texas Medical Branch at Galveston
mi
from
Galveston, TX
A Phase II Protocol of Arsenic Trioxide (Trisenox) in Subjects With Advanced Primary Carcinoma of the Liver
A Phase II Protocol of Arsenic Trioxide (Trisenox) in Subjects With Advanced Primary Carcinoma of the Liver
Status: Enrolling
Updated: 2/18/2016
University of Texas Medical Branch at Galveston
mi
from
Galveston, TX
Click here to add this to my saved trials
Randomized Trial of Suicide Gene Therapy and Prostate Cancer
A Randomized, Controlled Trial of Replication-Competent Adenovirus-Mediated Suicide Gene Therapy in Combination With IMRT Versus IMRT Alone for the Treatment of Newly-Diagnosed Prostate Cancer With an Intermediate Risk Profile
Status: Enrolling
Updated:  2/18/2016
Johns Hopkins University School of Medicine
mi
from
Baltimore, MD
Randomized Trial of Suicide Gene Therapy and Prostate Cancer
A Randomized, Controlled Trial of Replication-Competent Adenovirus-Mediated Suicide Gene Therapy in Combination With IMRT Versus IMRT Alone for the Treatment of Newly-Diagnosed Prostate Cancer With an Intermediate Risk Profile
Status: Enrolling
Updated: 2/18/2016
Johns Hopkins University School of Medicine
mi
from
Baltimore, MD
Click here to add this to my saved trials
Randomized Trial of Suicide Gene Therapy and Prostate Cancer
A Randomized, Controlled Trial of Replication-Competent Adenovirus-Mediated Suicide Gene Therapy in Combination With IMRT Versus IMRT Alone for the Treatment of Newly-Diagnosed Prostate Cancer With an Intermediate Risk Profile
Status: Enrolling
Updated:  2/18/2016
Henry Ford Health System
mi
from
Detroit, MI
Randomized Trial of Suicide Gene Therapy and Prostate Cancer
A Randomized, Controlled Trial of Replication-Competent Adenovirus-Mediated Suicide Gene Therapy in Combination With IMRT Versus IMRT Alone for the Treatment of Newly-Diagnosed Prostate Cancer With an Intermediate Risk Profile
Status: Enrolling
Updated: 2/18/2016
Henry Ford Health System
mi
from
Detroit, MI
Click here to add this to my saved trials
Assessing Ear Damage in Young Cancer Patients Treated With Cisplatin
A Group-Wide, Prospective Study of Ototoxicity Assessment in Children Receiving Cisplatin Chemotherapy
Status: Enrolling
Updated:  2/19/2016
UAB Comprehensive Cancer Center
mi
from
Birmingham, AL
Assessing Ear Damage in Young Cancer Patients Treated With Cisplatin
A Group-Wide, Prospective Study of Ototoxicity Assessment in Children Receiving Cisplatin Chemotherapy
Status: Enrolling
Updated: 2/19/2016
UAB Comprehensive Cancer Center
mi
from
Birmingham, AL
Click here to add this to my saved trials
Assessing Ear Damage in Young Cancer Patients Treated With Cisplatin
A Group-Wide, Prospective Study of Ototoxicity Assessment in Children Receiving Cisplatin Chemotherapy
Status: Enrolling
Updated:  2/19/2016
Arkansas Cancer Research Center at University of Arkansas for Medical Sciences
mi
from
Little Rock, AR
Assessing Ear Damage in Young Cancer Patients Treated With Cisplatin
A Group-Wide, Prospective Study of Ototoxicity Assessment in Children Receiving Cisplatin Chemotherapy
Status: Enrolling
Updated: 2/19/2016
Arkansas Cancer Research Center at University of Arkansas for Medical Sciences
mi
from
Little Rock, AR
Click here to add this to my saved trials
Assessing Ear Damage in Young Cancer Patients Treated With Cisplatin
A Group-Wide, Prospective Study of Ototoxicity Assessment in Children Receiving Cisplatin Chemotherapy
Status: Enrolling
Updated:  2/19/2016
Childrens Hospital Los Angeles
mi
from
Los Angeles, CA
Assessing Ear Damage in Young Cancer Patients Treated With Cisplatin
A Group-Wide, Prospective Study of Ototoxicity Assessment in Children Receiving Cisplatin Chemotherapy
Status: Enrolling
Updated: 2/19/2016
Childrens Hospital Los Angeles
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Assessing Ear Damage in Young Cancer Patients Treated With Cisplatin
A Group-Wide, Prospective Study of Ototoxicity Assessment in Children Receiving Cisplatin Chemotherapy
Status: Enrolling
Updated:  2/19/2016
Children's Hospital Central California
mi
from
Madera, CA
Assessing Ear Damage in Young Cancer Patients Treated With Cisplatin
A Group-Wide, Prospective Study of Ototoxicity Assessment in Children Receiving Cisplatin Chemotherapy
Status: Enrolling
Updated: 2/19/2016
Children's Hospital Central California
mi
from
Madera, CA
Click here to add this to my saved trials
Assessing Ear Damage in Young Cancer Patients Treated With Cisplatin
A Group-Wide, Prospective Study of Ototoxicity Assessment in Children Receiving Cisplatin Chemotherapy
Status: Enrolling
Updated:  2/19/2016
Rady Children's Hospital - San Diego
mi
from
San Diego, CA
Assessing Ear Damage in Young Cancer Patients Treated With Cisplatin
A Group-Wide, Prospective Study of Ototoxicity Assessment in Children Receiving Cisplatin Chemotherapy
Status: Enrolling
Updated: 2/19/2016
Rady Children's Hospital - San Diego
mi
from
San Diego, CA
Click here to add this to my saved trials
Assessing Ear Damage in Young Cancer Patients Treated With Cisplatin
A Group-Wide, Prospective Study of Ototoxicity Assessment in Children Receiving Cisplatin Chemotherapy
Status: Enrolling
Updated:  2/19/2016
UCSF Helen Diller Family Comprehensive Cancer Center
mi
from
San Francisco, CA
Assessing Ear Damage in Young Cancer Patients Treated With Cisplatin
A Group-Wide, Prospective Study of Ototoxicity Assessment in Children Receiving Cisplatin Chemotherapy
Status: Enrolling
Updated: 2/19/2016
UCSF Helen Diller Family Comprehensive Cancer Center
mi
from
San Francisco, CA
Click here to add this to my saved trials
Assessing Ear Damage in Young Cancer Patients Treated With Cisplatin
A Group-Wide, Prospective Study of Ototoxicity Assessment in Children Receiving Cisplatin Chemotherapy
Status: Enrolling
Updated:  2/19/2016
Connecticut Children's Medical Center
mi
from
Hartford, CT
Assessing Ear Damage in Young Cancer Patients Treated With Cisplatin
A Group-Wide, Prospective Study of Ototoxicity Assessment in Children Receiving Cisplatin Chemotherapy
Status: Enrolling
Updated: 2/19/2016
Connecticut Children's Medical Center
mi
from
Hartford, CT
Click here to add this to my saved trials
Assessing Ear Damage in Young Cancer Patients Treated With Cisplatin
A Group-Wide, Prospective Study of Ototoxicity Assessment in Children Receiving Cisplatin Chemotherapy
Status: Enrolling
Updated:  2/19/2016
Yale Cancer Center
mi
from
New Haven, CT
Assessing Ear Damage in Young Cancer Patients Treated With Cisplatin
A Group-Wide, Prospective Study of Ototoxicity Assessment in Children Receiving Cisplatin Chemotherapy
Status: Enrolling
Updated: 2/19/2016
Yale Cancer Center
mi
from
New Haven, CT
Click here to add this to my saved trials
Assessing Ear Damage in Young Cancer Patients Treated With Cisplatin
A Group-Wide, Prospective Study of Ototoxicity Assessment in Children Receiving Cisplatin Chemotherapy
Status: Enrolling
Updated:  2/19/2016
Alfred I. duPont Hospital for Children
mi
from
Wilmington, DE
Assessing Ear Damage in Young Cancer Patients Treated With Cisplatin
A Group-Wide, Prospective Study of Ototoxicity Assessment in Children Receiving Cisplatin Chemotherapy
Status: Enrolling
Updated: 2/19/2016
Alfred I. duPont Hospital for Children
mi
from
Wilmington, DE
Click here to add this to my saved trials
Assessing Ear Damage in Young Cancer Patients Treated With Cisplatin
A Group-Wide, Prospective Study of Ototoxicity Assessment in Children Receiving Cisplatin Chemotherapy
Status: Enrolling
Updated:  2/19/2016
Lee Cancer Care of Lee Memorial Health System
mi
from
Fort Myers, FL
Assessing Ear Damage in Young Cancer Patients Treated With Cisplatin
A Group-Wide, Prospective Study of Ototoxicity Assessment in Children Receiving Cisplatin Chemotherapy
Status: Enrolling
Updated: 2/19/2016
Lee Cancer Care of Lee Memorial Health System
mi
from
Fort Myers, FL
Click here to add this to my saved trials
Assessing Ear Damage in Young Cancer Patients Treated With Cisplatin
A Group-Wide, Prospective Study of Ototoxicity Assessment in Children Receiving Cisplatin Chemotherapy
Status: Enrolling
Updated:  2/19/2016
Nemours Children's Clinic
mi
from
Jacksonville, FL
Assessing Ear Damage in Young Cancer Patients Treated With Cisplatin
A Group-Wide, Prospective Study of Ototoxicity Assessment in Children Receiving Cisplatin Chemotherapy
Status: Enrolling
Updated: 2/19/2016
Nemours Children's Clinic
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Assessing Ear Damage in Young Cancer Patients Treated With Cisplatin
A Group-Wide, Prospective Study of Ototoxicity Assessment in Children Receiving Cisplatin Chemotherapy
Status: Enrolling
Updated:  2/19/2016
Florida Hospital Cancer Institute at Florida Hospital Orlando
mi
from
Orlando, FL
Assessing Ear Damage in Young Cancer Patients Treated With Cisplatin
A Group-Wide, Prospective Study of Ototoxicity Assessment in Children Receiving Cisplatin Chemotherapy
Status: Enrolling
Updated: 2/19/2016
Florida Hospital Cancer Institute at Florida Hospital Orlando
mi
from
Orlando, FL
Click here to add this to my saved trials
Assessing Ear Damage in Young Cancer Patients Treated With Cisplatin
A Group-Wide, Prospective Study of Ototoxicity Assessment in Children Receiving Cisplatin Chemotherapy
Status: Enrolling
Updated:  2/19/2016
Nemours Children's Clinic - Orlando
mi
from
Orlando, FL
Assessing Ear Damage in Young Cancer Patients Treated With Cisplatin
A Group-Wide, Prospective Study of Ototoxicity Assessment in Children Receiving Cisplatin Chemotherapy
Status: Enrolling
Updated: 2/19/2016
Nemours Children's Clinic - Orlando
mi
from
Orlando, FL
Click here to add this to my saved trials
Assessing Ear Damage in Young Cancer Patients Treated With Cisplatin
A Group-Wide, Prospective Study of Ototoxicity Assessment in Children Receiving Cisplatin Chemotherapy
Status: Enrolling
Updated:  2/19/2016
Nemours Children's Clinic - Pensacola
mi
from
Pensacola, FL
Assessing Ear Damage in Young Cancer Patients Treated With Cisplatin
A Group-Wide, Prospective Study of Ototoxicity Assessment in Children Receiving Cisplatin Chemotherapy
Status: Enrolling
Updated: 2/19/2016
Nemours Children's Clinic - Pensacola
mi
from
Pensacola, FL
Click here to add this to my saved trials